Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis.
Paolo MarchettiAndrea BotticelliAntonio Paolo AsciertoGiuseppe CuriglianoDiana GiannarelliPublished in: Journal of translational medicine (2020)
The combination of ipilimumab plus nivolumab seems to be superior to nivolumab alone in cancer patients, regardless of histology.
Keyphrases